Novel applications and contexts for the cognitive packet network

Autonomic communication, which is the development of self-configuring, self-adapting, self-optimising and self-healing communication systems, has gained much attention in the network research community. This can be explained by the increasing demand for more sophisticated networking technologies with physical realities that possess computation capabilities and can operate successfully with minimum human intervention. Such systems are driving innovative applications and services that improve the quality of life of citizens both socially and economically. Furthermore, autonomic communication, because of its decentralised approach to communication, is also being explored by the research community as an alternative to centralised control infrastructures for efficient management of large networks. This thesis studies one of the successful contributions in the autonomic communication research, the Cognitive Packet Network (CPN). CPN is a highly scalable adaptive routing protocol that allows for decentralised control in communication. Consequently, CPN has achieved significant successes, and because of the direction of research, we expect it to continue to find relevance. To investigate this hypothesis, we research new applications and contexts for CPN. This thesis first studies Information-Centric Networking (ICN), a future Internet architecture proposal. ICN adopts a data-centric approach such that contents are directly addressable at the network level and in-network caching is easily supported. An optimal caching strategy for an information-centric network is first analysed, and approximate solutions are developed and evaluated. Furthermore, a CPN inspired forwarding strategy for directing requests in such a way that exploits the in-network caching capability of ICN is proposed. The proposed strategy is evaluated via discrete event simulations and shown to be more effective in its search for local cache hits compared to the conventional methods. Finally, CPN is proposed to implement the routing system of an Emergency Cyber-Physical System for guiding evacuees in confined spaces in emergency situations. By exploiting CPN’s QoS capabilities, different paths are assigned to evacuees based on their ongoing health conditions using well-defined path metrics. The proposed system is evaluated via discrete-event simulations and shown to improve survival chances compared to a static system that treats evacuees in the same way.Open Acces

Routing Diverse Crowds in Emergency with Dynamic Grouping

Evacuee routing algorithms in emergency typically adopt one single criterion to compute desired paths and ignore the specific requirements of users caused by different physical strength, mobility and level of resistance to hazard. In this paper, we present a quality of service (QoS) driven multi-path routing algorithm to provide diverse paths for different categories of evacuees. This algorithm borrows the concept of Cognitive Packet Network (CPN), which is a flexible protocol that can rapidly solve optimal solution for any user-defined goal function. Spatial information regarding the location and spread of hazards is taken into consideration to avoid that evacuees be directed towards hazardous zones. Furthermore, since previous emergency navigation algorithms are normally insensitive to sudden changes in the hazard environment such as abrupt congestion or injury of civilians, evacuees are dynamically assigned to several groups to adapt their course of action with regard to their on-going physical condition and environments. Simulation results indicate that the proposed algorithm which is sensitive to the needs of evacuees produces better results than the use of a single metric. Simulations also show that the use of dynamic grouping to adjust the evacuees' category and routing algorithms with regard for their on-going health conditions and mobility, can achieve higher survival rates.Comment: Contains 6 pages, 5 pages. Accepted by PerNEM' 201

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo